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Priming of human naive CD4 ؉ T cells via CD5 costimulation requires IL-6 for optimal Th17 development
With interest we read the letter by Ayyoub and coworkers who compare the efficacy of Th17 differentiation from naive FOXP3 ϩ CD25 ϩ CD127 Ϫ NTregs and conventional naive T cells. 1 We previously reported that compared with CD28, alternative costimulation via CD5 enhanced Th17 differentiation from CD4 ϩ CD45RA ϩ CD4RO Ϫ naive T cells. 2 CD5 promotes Th17 development through elevation of IL-23R expression, resulting in prolonged STAT3 activation and enhanced levels of ROR-␥t. Ayyoub and coworkers also observed increased Th17 induction in naive CD4 ϩ T cells by CD5. Costimulation of NTregs via CD28 or CD5 both induce more Th17, from which the authors conclude that Th17 differentiation from conventional naive CD4 ϩ T cells is less efficient. We are pleased that our data on naive CD4 ϩ T cells are confirmed, but observed a relatively weak efficiency of Th17 differentiation using naive CD4 ϩ T cells. Moreover, no enhanced CD5-mediated expression of IL-23R and ROR-␥t was observed. We noticed that the experiments were performed in absence of IL-6, which has been reported to be required for optimal Th17 development. 3 Although not shown in our publication, we extensively investigated the contribution of IL-6 in the development of Th17 cells from naive CD4 ϩ T cells ( Figure 1 ). This data underlines the importance of IL-6 in Th17 development, especially on CD5 costimulation. Without IL-6, CD5 costimulation was still superior for Th17 induction, in agreement with Ayyoub et al's findings, but the efficiency of Th17 differentiation was strongly reduced ( Figure 1A ). In mice, Nishihara and coworkers showed that IL-6 requirement of conventional naive CD4 ϩ T cells for Th17 development is mediated by STAT3. 4 Indeed, omission of IL-6 abrogated STAT3 activation by CD28 or CD5 costimulation within the first 18 hours ( Figure 1B ). Especially for CD5 costimulation, this was followed by less pSTAT3 induction at later time points ( Figure 1B ). In line with this, IL-23R levels were also decreased in the absence of IL-6 ( Figure 1C ). Again, the strongest impact was observed on CD5-stimulated cells (Ϯ 80% reduction vs Ϯ 35% with CD28, P Ͻ .05, paired t test, n ϭ 3). As expected, 2 this also correlated with strongly decreased levels of ROR-␥t (P Ͻ .05, paired t test, n ϭ 3; Figure 1D ). Thus, IL-6 plays an important role in Th17 differentiation from naive CD4 ϩ T cells, not only on classic CD28 stimulation, 3 but even more strongly in CD5 stimulation. The lack of IL-6 may explain why Ayyoub and coworkers did not observe increased IL-23R or ROR-␥t in CD5-stimulated naive CD4 ϩ T cells. Interestingly, their data also show that NTregs still efficiently form Th17 without IL-6. This may reflect earlier observations showing reduced IL-6R signaling in natural Tregs compared with CD4 ϩ CD25 Ϫ T cells and only weak IL-6-induced STAT3 activation in Tregs compared with strong pSTAT3 induction in CD4 ϩ CD25 Ϫ T cells. 5 It is tempting to speculate that the latter also explains why CD5 is not superior to CD28 in NTreg costimulation. Taken together, the data of Ayyoub and coworkers show interesting new insights. To ascertain, however, whether Th17 development from NTregs is superior to that from conventional naive CD4 ϩ T cells, the concept that in different CD4 ϩ 
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Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT Allogeneic hematopoietic stem cell transplantation (HSCT) can grant long-term control and cure of acute myeloid leukemia (AML) thanks to the antitumor effect of the transplanted immune system. Still, relapse remains an open issue: in the haploidentical setting, we and others demonstrated that more than one-third of posttransplantation relapses are due to the de novo genomic loss of patient-specific HLA in leukemic blasts, which favors immune evasion from donor T cells. 1, 2 Although highly relevant in the haploidentical context, HLA loss has been poorly assessed after matched unrelated donor (MUD) HSCT, 3 which is 10 times more frequent in clinical practice. 4 Here we report on a 36-year-old woman with normal karyotype AML, positive for the FLT3 internal tandem duplication (ITD) at diagnosis (clinical course in Figure 1A ). The patient achieved complete remission after standard induction and 2 courses of consolidation chemotherapy, followed by myeloablative HSCT from a MUD (10/12 HLA matched, donor 1 in Figure 1B) . Disease relapse occurred after 10 months, and was controlled for more than 2 years by salvage chemotherapy followed by serial donor lymphocyte infusions (DLIs). Thereafter, a second relapse occurred, requiring 2 cycles of chemotherapy and a second allogeneic HSCT from a different MUD (9/12 and 11/12 HLA matched with the patient and the first donor, respectively, donor 2 in Figure 1B) . After 6 months from the second HSCT, a third relapse occurred (boxed in gray in Figure 1A) . Interestingly, this time leukemia resulted negative for the FLT3-ITD mutation, prompting further investigation. 5 HLA molecular typing and whole-genome single nucleotide polymorphism analysis were comparatively performed on leukemia at diagnosis and at third relapse, demonstrating de novo acquired uniparental disomy (UPD) of a large region of chromosome 6p. The genomic alteration spanned approximately 40 Mb and resulted in the loss of the HLA haplotype encompassing the C*02:02 and DPB1*04:02 mismatched alleles ( Figure 1B and C), with the same mechanism described for relapses after haploidentical HSCT. 1, 2 This observation suggests that a primeval leukemic clone, even though negative for FLT3-ITD (mapped to chromosome 13), may have persisted during the course of treatments and reappeared upon the immune advantage granted by genomic HLA
